News

For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.

27th Sep 12

Pharmaxis Receives Maximum Extension of Term to Major European Patent

Pharmaceutical company Pharmaxis (ASX: PXS) is pleased to announce it has received notification from the German Patent Office that the European Patent for both Aridol® and Bronchitol® has been extended by five years.

The extension to the patent, through the granting of a Supplementary Protection Certificate (SPC) is for the maximum allowable period of 5 years which will see the Aridol and Bronchitol patent extended from 24th February 2015 to 23rd February 2020.

 

Read full media release - pdf
2nd Aug 12

Australian Drug Discovery Listed On The PBS For Cystic Fibrosis

A drug discovered and developed in Australia has been listed on the Pharmaceutical Benefits Scheme (PBS) for the treatment of cystic fibrosis: one of the world’s most common life-shortening genetic diseases.

Bronchitol® (mannitol) is the first of a new class of cystic fibrosis medicines designed to tackle one of the fundamental problems that leads to loss of lung function.  It has been the subject of one of the largest clinical trial programs undertaken in cystic fibrosis - conducted in over 600 patients in 10 countries around the world and co-ordinated by scientists based in Australia. 

 

Read full media release - pdf
2nd Aug 12

US FDA Accepts Bronchitol New Drug Application for Review

Pharmaceutical company Pharmaxis (ASX: PXS) is pleased to announce it has received notification from the United States Food and Drug Administration (FDA) that the New Drug Application (NDA) for its cystic fibrosis product, Bronchitol®, has been accepted for standard review.

The FDA has assigned the Bronchitol application a Prescription Drug User Fee Act (PDUFA) goal date of 18 March, 2013.  If the application is approved, Pharmaxis anticipates Bronchitol could be available for US patients with cystic fibrosis in the second quarter of 2013.

 

Read full media release - pdf